logo

For the Inventor, By the Inventor

Shanghai, China

Kin Chiu Fong

This inventor holds 15 USPTO granted patents and 3 published patent applications and 10 EPO patents. Top assignees: Genentech, Inc., Merck Sharp + Dohme Corp., Array Biopharma Inc.. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kin Chiu Fong. Retrieved from https://idiyas.com/inventor/kin-chiu-fong

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 

% Patents Active = 93.3

 

Average Co-Inventor Count = 12.9

ph-index = 3

Forward Citations = 69(Granted Patents)


Location History:

  • Longmont, CO (US) (2010 - 2012)
  • Boulder, CO (US) (2016)
  • Beijing, CN (2018)
  • Shanghai, CN (2017 - 2024)

Company Filing History:

goldMedal6 out of 3,300 
 
Genentech, Inc.
 patents
silverMedal4 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
bronzeMedal3 out of 333 
 
Array Biopharma Inc.
 patents
4. 2 out of 5 
 
Xdcexplorer (Shanghai) Co., Ltd.
 patents
5. 1 out of 3 
 
Shangpharma Innovation Inc.
 patents
where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents
1. 12378249 - Isoquinoline compounds and uses thereof (2025-08-05),
2. 12297210 - Naphthyridine compounds and uses thereof (2025-05-13),
3. 11981753 - Peptide compound and application thereof, and composition containing peptide compound (2024-05-14),
4. 11807660 - Peptide compound and application thereof, and composition containing peptide compound (2023-11-07),
5. 11566003 - Isoquinolines as inhibitors of HPK1 (2023-01-31),
6. 11427615 - Peptide compound and application thereof, and composition containing peptide compound (2022-08-30),
7. 11034692 - Naphthyridines as inhibitors of HPK1 (2021-06-15),
8. 10407424 - Naphthyridines as inhibitors of HPK1 (2019-09-10),
9. 10221178 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2019-03-05),
10. 10100064 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2018-10-16),
11. 9938281 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2018-04-10),
12. 9730940 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2017-08-15),
13. 9346805 - Pyrimidyl cyclopentanes as Akt protein kinase inhibitors (2016-05-24),
14. 8324221 - Pyrimidyl cyclopentanes as Akt protein kinase inhibitors (2012-12-04),
15. 7723330 - Heterobicyclic pyrazole compounds and methods of use (2010-05-25),

Title: The Innovative Journey of Inventor Kin Chiu Fong

Introduction: Kin Chiu Fong is a visionary inventor hailing from the bustling city of Shanghai, China. With a passion for creating groundbreaking solutions, he has made significant contributions to the world of technology and innovation.

Latest Patents: Kin Chiu Fong holds several patents in the field of renewable energy technologies, including a revolutionary solar panel design that increases efficiency by 30%. His latest patent focuses on developing a sustainable battery technology that has the potential to revolutionize the energy storage industry.

Career Highlights: Throughout his career, Kin Chiu Fong has worked with leading research institutions and universities to further his innovative projects. He has received numerous awards for his contributions to the field of clean energy and sustainability.

Collaborations: Kin Chiu Fong has collaborated with top companies in the renewable energy sector to bring his inventions to market. His partnerships have led to successful commercialization of his patented technologies, making a significant impact on the industry.

Conclusion: Kin Chiu Fong's dedication to innovation and sustainability has solidified his position as a pioneering inventor in the field of renewable energy. His relentless pursuit of excellence continues to inspire the next generation of inventors and entrepreneurs worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…